The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ISAL 2019 | Targeted therapy for AML: current outlook and future potential
Lars Bullinger
• 24 Feb 2019
Speaking from the International Symposium on Acute Leukemias (ISAL) 2019, held in Munich, Germany, Lars Bullinger, MD, of Charité University of Medicine, Berlin, Germany, talks to us about the current landscape and future role for targeted therapies in acute myeloid leukemia (AML).
